Morepen Laboratories quarterly results

Q2 FY27 · Jul–Sep 2026

₹ crore	Q2 FY27	Q2 FY26	Change
Revenue	747	412	+81.4%
EBITDA	123	30.7	+301.1%
EBITDA margin	16.5%	7.5%	+9.0 pts
Profit before tax	117	45.7	+155.0%
Net profit	88.9	40.9	+117.5%
EPS	₹1.62	₹0.75	+116.0%

Every quarter

₹ crore except per share

Tap a line for its trend	Q2 FY27Sep 2026	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024	Q4 FY24Mar 2024	Q3 FY24Dec 2023	Earlier quartersAlpha Plus

Expenses
	747	570	485	484	412	425	466	453	438	455	423	445	Earlier quartersEvery year the company has filed comes with Alpha Plus.
	8.7	5.2	8.5	3.8	4.6	4.4	4.6	5.3	5.0	3.4	4.2	4.1
	755	575	493	488	416	430	470	458	443	459	427	449
	412	328	291	294	221	238	268	240	256	235	220	236
	7.0	9.6	17.7	15.8	32.0	17.0	71.3	40.7	39.3	56.0	30.1	45.6
	−30.0	−19.3	−8.7	−12.6	11.6	7.6	−24.0	10.5	−25.4	−8.2	6.2	−9.2
	79.7	62.4	58.8	62.1	56.7	55.2	57.0	54.3	49.7	48.0	47.9	46.8
	5.2	4.8	3.9	4.3	4.2	4.0	4.7	1.3	1.2	1.2	0.8	2.2
	10.1	8.3	5.7	10.4	11.3	9.0	16.5	4.9	1.9	5.7	9.6	8.4
	155	106	102	78.4	60.0	83.5	50.9	71.7	73.9	72.8	70.2	75.2
	639	501	470	453	396	414	445	423	397	410	385	405
	123	82.5	24.4	46.3	30.7	24.2	42.2	36.1	44.1	51.6	48.4	50.6
	113	74.2	18.7	35.9	19.4	15.1	25.8	31.2	42.2	45.9	38.8	42.1
Profit
	117	74.5	23.3	35.4	19.9	15.5	25.7	35.2	46.0	48.2	42.2	44.0
	0.0	0.0	0.0	0.0	25.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	117	74.5	23.3	35.4	45.7	15.5	25.7	35.2	46.0	48.2	42.2	44.0
	20.7	18.2	−0.9	8.4	4.7	4.1	0.7	8.5	11.2	12.0	13.9	12.0
	6.9	−0.0	8.5	−0.5	0.0	0.0	4.7	0.0	0.0	0.0	−0.4	0.0
	27.6	18.2	7.6	7.9	4.7	4.1	5.4	8.5	11.2	12.0	13.5	12.0
	0.0	0.1	0.0	0.0	−0.2	−0.7	0.0	0.0	0.0	0.0	−0.5	−0.0
	88.9	56.4	15.7	27.5	40.9	10.7	20.3	26.7	34.8	36.2	28.3	32.0
	88.9	56.3	15.7	27.5	41.0	11.4	20.3	26.7	34.8	36.2	28.7	32.0
	0.1	0.2	6.4	0.6	−1.4	0.6	−0.8	−0.4	−1.1	2.6	−2.0	−0.0
	89.0	56.6	22.1	28.1	39.5	11.3	19.5	26.3	33.7	38.7	26.2	32.0
	—	—	15.7	27.5	40.9	10.7	—	—	—	—	28.3	—
Per share
	₹1.62	₹1.03	₹0.28	₹0.50	₹0.75	₹0.20	₹0.35	₹0.49	₹0.65	₹0.71	₹0.54	₹0.63
	₹1.62	₹1.03	₹0.28	₹0.50	₹0.75	₹0.20	₹0.35	₹0.49	₹0.65	₹0.71	₹0.54	₹0.63
Other comprehensive income — detail
	0.1	0.2	6.4	0.6	−1.4	0.6	−0.8	—	—	—	—	—
	0.1	0.2	6.2	0.8	−1.5	0.8	−1.1	−0.6	−1.5	3.4	−3.0	−0.0
	0.0	0.0	0.0	0.2	−0.4	0.2	−0.3	—	—	—	—	—
	—	—	—	—	—	—	—	−0.1	−0.4	0.9	−0.8	−0.0
	−0.0	—	0.2	0.0	—	—	0.0	—	—	—	0.2	—
	0.0	0.0	0.0	0.0	0.2	0.0	0.0	—	—	—	—	—
	—	56.4	—	27.5	—	10.7	—	—	—	—	—	—
Per share — as-filed variants
	₹1.62	₹1.03	₹0.28	₹0.50	₹0.75	₹0.20	₹0.35	₹0.49	₹0.65	₹0.71	₹0.54	₹0.63
	₹1.62	₹1.03	₹0.28	₹0.50	₹0.75	₹0.20	₹0.35	₹0.49	₹0.65	₹0.71	₹0.54	₹0.63
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	358	251	185	187	147	163	150	162	168	172	167	173
	47.9%	44.1%	38.2%	38.6%	35.8%	38.3%	32.2%	35.8%	38.3%	37.9%	39.4%	38.8%
Adjusted (ex-exceptional items) — derived
	117	74.5	23.3	35.4	19.9	15.5	25.7	35.2	46.0	48.2	42.2	44.0
	0.0	0.0	0.0	0.0	25.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	88.9	56.4	15.7	27.5	17.7	10.7	20.3	26.7	34.8	36.2	28.3	32.0
	₹1.62	₹1.03	₹0.28	₹0.50	₹0.32	₹0.20	₹0.35	₹0.49	₹0.65	₹0.71	₹0.54	₹0.63

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

MOREPENLAB₹125.58

Morepen Laboratories Limited

· Pharma & Health

Annual Quarterly₹ CrorePeersIOLCP INNOVACAP FDC ORCHPHARMA SENORES SANOFI GUJTHEM RPGLIFEMcap ₹6,881 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026	Q2 FY27 30/09/2026
Revenue from Operations	444.6	423.1	455.2	437.7	452.8	465.9	425.2	411.6	484.2	484.7	570.1	746.5
Other Income	4.1	4.2	3.4	5.0	5.3	4.6	4.4	4.6	3.8	8.5	5.2	8.7
Total Income	448.6	427.3	458.6	442.7	458.1	470.5	429.6	416.2	488.0	493.2	575.3	755.2
Expenses
+ Cost of Materials Consumed	235.6	220.3	235.0	256.2	239.5	268.4	237.7	220.6	294.2	290.6	328.4	411.9
+ Purchases of Stock-in-Trade	45.6	30.1	56.0	39.3	40.7	71.3	17.0	32.0	15.8	17.7	9.6	7.0
+ Changes in Inventories	-9.2	6.2	-8.2	-25.4	10.5	-24.0	7.6	11.6	-12.6	-8.7	-19.3	-30.0
+ Employee Benefit Expense	46.8	47.9	48.0	49.7	54.3	57.0	55.2	56.7	62.1	58.8	62.4	79.7
+ Finance Costs	2.2	0.8	1.2	1.2	1.3	4.7	4.0	4.2	4.3	3.9	4.8	5.2
+ Depreciation & Amortisation	8.4	9.6	5.7	1.9	4.9	16.5	9.0	11.3	10.4	5.7	8.3	10.1
+ Other Expenses	75.2	70.2	72.8	73.9	71.7	50.9	83.5	60.0	78.4	102.0	106.4	154.9
Total Expenses	404.6	385.1	410.5	396.7	422.9	444.8	414.1	396.3	452.5	469.9	500.8	638.6
EBITDA	50.6	48.4	51.6	44.1	36.1	42.2	24.2	30.7	46.3	24.4	82.5	123.1
EBIT	42.1	38.8	45.9	42.2	31.2	25.8	15.1	19.4	35.9	18.7	74.2	113.0
Profit
PBT before Exceptional Items	44.0	42.2	48.2	46.0	35.2	25.7	15.5	19.9	35.4	23.3	74.5	116.5
+ Exceptional Items	0.0	0.0	0.0	0.0	0.0	0.0	0.0	25.8	0.0	0.0	0.0	0.0
Pretax Income	44.0	42.2	48.2	46.0	35.2	25.7	15.5	45.7	35.4	23.3	74.5	116.5
+ Current Tax	12.0	13.9	12.0	11.2	8.5	0.7	4.1	4.7	8.4	-0.9	18.2	20.7
+ Deferred Tax	0.0	-0.4	0.0	0.0	0.0	4.7	0.0	0.0	-0.5	8.5	-0.0	6.9
Tax Expense	12.0	13.5	12.0	11.2	8.5	5.4	4.1	4.7	7.9	7.6	18.2	27.6
+ Share of Associates & JVs	-0.0	-0.5	0.0	0.0	0.0	0.0	-0.7	-0.2	0.0	0.0	0.1	0.0
Net Income	32.0	28.3	36.2	34.8	26.7	20.3	10.7	40.9	27.5	15.7	56.4	88.9
+ Net Income — Continuing Ops	32.0	28.7	36.2	34.8	26.7	20.3	11.4	41.0	27.5	15.7	56.3	88.9
+ Other Comprehensive Income	-0.0	-2.0	2.6	-1.1	-0.4	-0.8	0.6	-1.4	0.6	6.4	0.2	0.1
Total Comprehensive Income	32.0	26.2	38.7	33.7	26.3	19.5	11.3	39.5	28.1	22.1	56.6	89.0
Net Income to Common	—	28.3	—	—	—	—	10.7	40.9	27.5	15.7	—	—
Per Share
Basic EPS	0.63	0.54	0.71	0.65	0.49	0.35	0.20	0.75	0.50	0.28	1.03	1.62
Diluted EPS	0.63	0.54	0.71	0.65	0.49	0.35	0.20	0.75	0.50	0.28	1.03	1.62
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	-0.8	0.6	-1.4	0.6	6.4	0.2	0.1
+ Items NOT to be Reclassified to P&L	-0.0	-3.0	3.4	-1.5	-0.6	-1.1	0.8	-1.5	0.8	6.2	0.2	0.1
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	-0.3	0.2	-0.4	0.2	0.0	0.0	0.0
+ Tax on Items NOT to be Reclassified — alt tag	-0.0	-0.8	0.9	-0.4	-0.1	—	—	—	—	—	—	—
+ Items to be Reclassified to P&L	—	0.2	—	—	—	0.0	—	—	0.0	0.2	—	-0.0
+ Tax on Items to be Reclassified	—	—	—	—	—	0.0	0.0	0.2	0.0	0.0	0.0	0.0
Comprehensive Income — Owners of Parent	—	—	—	—	—	—	10.7	—	27.5	—	56.4	—
Per Share — as-filed variants
Basic EPS — Continuing Operations	0.63	0.54	0.71	0.65	0.49	0.35	0.20	0.75	0.50	0.28	1.03	1.62
Diluted EPS — Continuing Operations	0.63	0.54	0.71	0.65	0.49	0.35	0.20	0.75	0.50	0.28	1.03	1.62
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	172.5	166.5	172.4	167.6	162.1	150.1	162.9	147.4	186.8	185.2	251.4	357.7
Gross Margin %	38.81	39.37	37.87	38.30	35.81	32.22	38.30	35.81	38.59	38.21	44.10	47.91
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	44.0	42.2	48.2	46.0	35.2	25.7	15.5	19.9	35.4	23.3	74.5	116.5
− Exceptional Items (reconciliation)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	25.8	0.0	0.0	0.0	0.0
Net Income Adj (tax-effected)	32.0	28.3	36.2	34.8	26.7	20.3	10.7	17.7	27.5	15.7	56.4	88.9
EPS Adj	0.63	0.54	0.71	0.65	0.49	0.35	0.20	0.32	0.50	0.28	1.03	1.62
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	2.00	2.00	2.00	—	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
Paid Up Equity Capital	102.2	102.2	102.2	109.6	109.6	109.6	109.6	109.6	109.6	109.6	109.6	109.6

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q2 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Morepen Laboratories Q2 FY27 results (July–September 2026)

Filed with NSE on Tuesday, 27 October 2026 at 1:31 pm IST

Morepen Laboratories (NSE: MOREPENLAB) reported its Q2 FY27 results (July–September 2026) on Tuesday, 27 October 2026 at 1:31 pm IST. Consolidated net profit was ₹88.9 crore, up 117.5% from ₹40.9 crore in Q2 FY26 and up 57.6% from ₹56.4 crore in Q1 FY27. Revenue from operations was ₹747 crore, up 81.4% year on year and up 30.9% from the previous quarter.

Q2 FY26 results (a year earlier): 14 November 2025
Q3 FY27 results due by: 14 February 2027

Q2 FY27 at a glance · consolidated

Net profit: ₹88.9 Cr+117.5% vs Q2 FY26+57.6% vs Q1 FY27
Revenue from operations: ₹747 Cr+81.4% vs Q2 FY26+30.9% vs Q1 FY27
Operating margin (EBIT): 15.1%+10.4 pts vs Q2 FY26+2.1 pts vs Q1 FY27EBIT ₹113 Cr
EBITDA: ₹123 Cr+301.1% vs Q2 FY26+49.2% vs Q1 FY27margin 16.5%
Earnings per share (basic): ₹1.62+116.0% vs Q2 FY26+57.3% vs Q1 FY27
Net profit margin: 11.9%+2.0 pts vs Q2 FY26+2.0 pts vs Q1 FY27

Questions

What was Morepen Laboratories' net profit in Q2 FY27?

Consolidated net profit was ₹88.9 crore, up 117.5% from ₹40.9 crore in Q2 FY26 and up 57.6% from ₹56.4 crore in Q1 FY27.

What was Morepen Laboratories' revenue in Q2 FY27?

Revenue from operations was ₹747 crore, up 81.4% year on year and up 30.9% from the previous quarter.

What was Morepen Laboratories' operating margin in Q2 FY27?

Operating profit (EBIT — revenue less operating expenses, before finance costs and other income) was ₹113 crore, a margin of 15.1%, against 13.0% in Q1 FY27 and 4.7% in Q2 FY26. EBITDA was ₹123 crore, 16.5% of revenue.

How were Morepen Laboratories' Q2 FY27 results?

Both grew from a year earlier: net profit was up 117.5% at ₹88.9 crore and revenue was up 81.4% at ₹747 crore. The operating margin was 15.1%, up 10.4 percentage points from 4.7% a year earlier. Against Q1 FY27, net profit was up 57.6% and revenue up 30.9%.

What was Morepen Laboratories' net profit in the first half of FY27?

Consolidated net profit for the first half of FY27 (April–September 2026) was ₹145 crore, up 181.5% from ₹51.6 crore in the same months a year earlier. Revenue from operations was ₹1,317 crore, up 57.3%.

What is Morepen Laboratories' net profit margin?

Morepen Laboratories' net profit margin was 11.9% in Q2 FY27 (net profit as a share of revenue from operations), against 9.9% in Q2 FY26 (up 2.0 percentage points). For FY26 as a whole it was 5.3%.

What was Morepen Laboratories' EPS in Q2 FY27?

Basic earnings per share were ₹1.62, against ₹0.75 in Q2 FY26.

What was Morepen Laboratories' net profit in FY26?

Consolidated net profit was ₹94.9 crore in FY26 (April 2025–March 2026), down 19.6% from ₹118 crore in FY25. It was ₹96.2 crore in FY24 and ₹38.7 crore in FY23: up 145.3% over three years, 34.9% a year on average.

When did Morepen Laboratories announce its Q2 FY27 results?

On Tuesday, 27 October 2026 at 1:31 pm IST, in its results filing to the stock exchanges. A year earlier it reported Q2 FY26 on 14 November 2025.

How has Morepen Laboratories' profit changed over the last four quarters?

Net profit by quarter: ₹27.5 crore in Q3 FY26, ₹15.7 crore in Q4 FY26, ₹56.4 crore in Q1 FY27 and ₹88.9 crore in Q2 FY27. That is ₹189 crore over the four quarters, up 91.2% from ₹98.6 crore in the four quarters before. Revenue from operations: ₹484 crore, ₹485 crore, ₹570 crore and ₹747 crore.

What was Morepen Laboratories' revenue in FY26?

Revenue from operations was ₹1,806 crore in FY26 (April 2025–March 2026), down 0.3% from ₹1,812 crore in FY25. It was ₹1,690 crore in FY24 and ₹1,418 crore in FY23: up 27.4% over three years, 8.4% a year on average.

When will Morepen Laboratories announce its Q3 FY27 results?

Q3 FY27 covers October–December 2026. Listed companies must publish quarterly results within 45 days of the quarter's end (SEBI listing rules, Regulation 33), so the results are due by 14 February 2027. The company tells the exchanges the date of the board meeting at least two working days before it.

Where do these Morepen Laboratories figures come from?

From Morepen Laboratories' own consolidated results filings to NSE, in ₹ crore as filed (Q2 FY27 on 27 October 2026). Growth compares the same consolidated figures a year and a quarter earlier.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.